Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the treatment of severely brain injured patients with
darbepoetin (a long acting form of erythropoietin) will be safe, and will reduce brain damage
by decreasing harmful levels of chemicals in the brain.